In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors

Cancer Immunology Immunotherapy

Volumn 47, Issue 5, 1999, Pages 265-271

  D'Angelica, Michael ^a   Karpoff, Howard ^a   Halterman, Marc ^c   Ellis, Jennifer ^a   Klimstra, David ^a   Edelstein, Diane ^b   Brownlee, Michael ^b   Federoff, Howard ^c   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Cytokines; Immunotherapy; Squamous tumors

Indexed keywords

BETA GALACTOSIDASE; INTERLEUKIN 2; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; LUNG CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032916801     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050530     Document Type: Article

References (49)

1. 1. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022
2. 2. Andersen JK, Garber DA, Meaney CA, Breakfield XO (1992) Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific promoter. Hum Gene Ther 3:487
3. 3. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E (1994) The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol 152:2324
4. 4. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA (1994) Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1:323
5. 5. Brody SL, Jaffe HA, Han SK, Wersto RP, Crystal RG (1994) Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 5:437
6. 6. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4 positive T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149:3627
7. 7. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice treated with interleukin 2 gene modified tumor cells. J. Exp Med 177:1127
8. 8. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
9. 9. Dubinett SM, Patrone L, Tobias J, Cochran AJ, Wen D, McBride WH (1993) Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother 36:156
10. 10. Eisenthal A, Skornick Y, Merimsky O, Hirsch R, Zakut V, Ron I, Chaitchik S (1993) Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors. Cancer immunology immunothe 37:233
11. 11. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397
12. 12. Fink DJ, Glorioso JC (1997) Herpes simplex virus-based vectors: problems and some solutions. Adv Neurol 72:149
13. 13. Fong YF, Federoff HJ, Brownlee M, Blumberg D, Blumgart LH, Brennan MF (1995) Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 22:723
14. 14. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217
15. 15. Geller AI (1997) Herpes simplex virus-1 plasmid vectors for gene transfer into neurons. Adv Neurol 72:143
16. 16. Geller AI, Federoff H (1991) The use of HSV-1 vectors to introduce heterologous genes into neurons: implications for gene therapy. In: Cohen-Haguenauer M, Boiron M (eds) Human gene transfer. John Libbey Eurotext, Montrouge, p 63
17. 17. Geller AI, Keyomarsi K, Bryan J, Pardee AB (1990) An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 87:8950
18. 18. Golumbek P, Lazenby A, Levitsky HI, Jaffee EM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells Engineered to secrete interleukin-4. Science 254:713
19. 19. Heike Y, Takahashi M, Kanegae Y, Sato Y, Saito I, Saijo N (1997) Interleukin-2 gene transduction into freshly isolated lung adenocarcinma cells with adenoviral vectors. Hum Gene Ther 8:1
20. 20. Herberman RB (1989) Interleukin-2 therapy of human cancer: potential benefits versus toxicity. J Clin Oncol 7:1
21. 21. Ho DY (1994) Amplicon-based herpes simplex virus vectors. Methods Cell Biol 43:191
22. 22. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or Interferon gamma. Proc Natl Aca Sci USA 90:2774
23. 23. Hogan SP, Foster PS, Tan X, Ramsay AJ (1998) Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J of Immunol 28:413
24. 24. Huard J, Goins WF, Glorioso JC (1995) Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Ther 2:385
25. 25. Iwanuma Y, Kato K, Yagita H, Okumura K (1995) Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene. Cancer Immunol Immunother 40:17
26. 26. Karpoff H, D'Angelica M, Blair S, Brownlee MD, Federoff H (1997) Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Investigation 99:799
27. 27. Lattime EC, Lee SS, Eiseniohr LC, Mastrangelo MJ (1996) In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 23:88
28. 28. Lattime EC, Lee SS, Eiseniohr LC, Mastrangelo MJ (1996) In situ cytokine gene transfection using vaccinia virus vectors (review. 98 references) Semin Oncol 23:88
29. 29. Lee RL, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA (1989) Cardiorespiratory effects of immuno-therapy with interleukin-2. J Clin Oncol 7:7
30. 30. Lotze MT (1992) T-cell growth factors and the treatment of patients with cancer. Clin Immunol Immunopathol 62:S47-S54
31. 31. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. J Am Med Assoc 256:3117
32. 32. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF, Fink DJ, Glorioso JC (1996) Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 93:11319
33. 33. Matory YL, Chang AE, Lipford EH, Braziel R, Hyatt CL, McDonald HD, Rosenberg SA (1985) Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod 4:377
34. 34. Mesri EM, Federoff HJ, Brownlee M (1995) Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice. Circ Res 76:161
35. 35. Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239
36. 36. Miyanohara A, Johnson PA, Elam RL, Dai Y, Witztum JL, Verma IM, Friedmann T (1992) Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX. New Biol 4:238
37. 37. Mule JJ, Yang JC, Afreniere RL, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139:285
38. 38. Pardoll D (1992) Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 4:1124
39. 39. Plautz GE, Yang Z, Wu B, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad of Science USA 90:4645
40. 40. Porgador A, Tzehoval E, Katz A, Vadai A, Vadai E, Revel M, Feldman M, Eisenbach L (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679
41. 41. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi, Scott B (1998) Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 21:211
42. 42. Roemer K, Friedmann T (1992) Concepts and strategies for human gene therapy. Eur J Biochem 208:211
43. 43. Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21
44. 44. Rubin JT (1993) Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest 11:460
45. 45. Schreiber H, Nettesheim P, Martin DH (1972) Rapid development of bronchiolo-alveolar squamous cell tumors in rats after intra-tracheal injection of 3-methylcholanthrene. J Natl Cancer Inst 49:541
46. 46. Scudeletti M, Filaci G, Imro MA, Giovanni M, DiGaetano M, Pierri I, Tongiani S, Indiveri F, Puppo F (1993) Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. Cancer Immunol Immunother 37:119
47. 47. Tung C, Federoff HJ, Brownlee M, Karpoff H, Weigel T, Brennan MF, Fong Y (1996) Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 7:2217
48. 48. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407
49. 49. Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC (1994) in vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 5:731